JAK1 and acute lymphoblastic leukemia: BI-3802 was shown to restore/enhance the effectiveness of imatinib, promoting increased apoptosis in the setting of GIST [121,150], and FX1 overcame resistance to the JAK1/2 inhibitor ruxolitinib in CRL2-rearranged ALL [151] and synergized with the EGFR inhibitor gefitinib in NSCLC [122], while WK499 synergized with chemotherapy in ALL [137].